Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Blau FarmaceuticaBSP:BLAU3 +1.60%83 EV-to-FCF is 7.74 as of Sep. 13, 2026, which is 49% below its 10-year median of 15.25. GuruFocus rates BSP:BLAU3 with a GF Score™ of 83/100 and a GF Value™ of R$10.77 (Fairly Valued). The stock has 8 warning signs investors should review. Among 567 Drug Manufacturers companies, Blau Farmaceutica ranks better than 84.3% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Blau Farmaceutica's Enterprise Value is R$2,302 Mil.
Blau Farmaceutica's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was R$297 Mil. Therefore, Blau Farmaceutica's EV-to-FCF for today is 7.74.
The historical rank and industry rank for Blau Farmaceutica's EV-to-FCF or its related term are showing as below:
BSP:BLAU3'
s EV-to-FCF Range Over the Past 10 Years
Min: -728.83 Med: 15.25 Max: 867.53
Current: 7.74
During the past 10 years, the highest EV-to-FCF of Blau Farmaceutica was 867.53. The lowest was -728.83. And the median was 15.25.
BSP:BLAU3's EV-to-FCF is ranked better than 84.3% of 567
companies
in the Drug Manufacturers industry
Industry Median: 19.52
vs BSP:BLAU3: 7.74
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Blau Farmaceutica's PE Ratio (TTM) for today is calculated as:
Blau Farmaceutica's share price for today is R$10.18.
Blau Farmaceutica's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$1.287.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Blau Farmaceutica EV-to-FCF Related Terms
Blau Farmaceutica EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Blau Farmaceutica's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:BLAU3 vs ZTS, UTHR, VTRS: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Blau Farmaceutica's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Blau Farmaceutica EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Blau Farmaceutica's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Blau Farmaceutica's EV-to-FCF falls into.
Blau Farmaceutica's current Enterprise Value is R$2,302 Mil.
Blau Farmaceutica's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$297 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Blau Farmaceutica (BSP:BLAU3) has a EV-to-FCF of 7.74 as of Sep. 13, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Blau Farmaceutica and its competitors. This is 49% below median its historical median of 15.25. According to the industry distribution chart, Blau Farmaceutica ranks #89 out of 567 companies in the Drug Manufacturers industry, placing it in the top 15.7%.
Is Blau Farmaceutica's EV-to-FCF too high?
Blau Farmaceutica's current EV-to-FCF of 7.74 is 49% below median its 10-year median of 15.25. The Drug Manufacturers industry median EV-to-FCF is 19.52. Blau Farmaceutica's value of 7.74 is 60.3% below this industry median. Based on the distribution chart, Blau Farmaceutica ranks #89 out of 567 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Blau Farmaceutica has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Blau Farmaceutica's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Blau Farmaceutica ranks #89 out of 567 companies for EV-to-FCF. This places Blau Farmaceutica in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 19.52. Blau Farmaceutica's value of 7.74 is 60.3% below this benchmark. While the company's 10-year median is 15.25 vs. the industry median of 19.52, Blau Farmaceutica has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 19.52, based on 567 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Blau Farmaceutica's current EV-to-FCF of 7.74 is 60.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Blau Farmaceutica and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 19.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Blau Farmaceutica's current EV-to-FCF is 7.74, which is 49% below median its own 10-year median of 15.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Blau Farmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Blau Farmaceutica (BSP:BLAU3) is currently considered Fairly Valued. The stock's GF Value™ is R$10.77, compared to a current price of R$10.18 — trading 5.5% below its estimated fair value. The current EV-to-FCF is 7.74, which is 49% below median its 10-year median of 15.25 and 60.3% below the Drug Manufacturers industry median of 19.52. Blau Farmaceutica's overall GF Score™ is 83/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Blau Farmaceutica (BSP:BLAU3), the current EV-to-FCF is 7.74 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Blau Farmaceutica (BSP:BLAU3) Overvalued in 2026?
Based on GuruFocus' analysis, Blau Farmaceutica stock appears to be undervalued.
The current stock price of R$10.18 is trading 5.5% below its estimated GF Value™ of R$10.77.
GuruFocus considers Blau Farmaceutica to be Fairly Valued.
Key valuation signals for BSP:BLAU3:
EV-to-FCF: 7.74 (49% below median its 10-year median of 15.25)
GF Value™: R$10.77 vs. price of R$10.18 (5.5% below fair value)
Industry Position: 60.3% below the Drug Manufacturers median (#89 of 567)
No single metric tells the full story. See the BSP:BLAU3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company's business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital's daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.
83GF Score
Get the complete analysis for BSP:BLAU3
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:BLAU3 has been successfully added to your 
